MPMark Portou

Mark Portou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mark Portou has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rotational Percutaneous Mechanical Thrombectomy for Acute and Subacute Limb Ischaemia: A Systematic Review and Proportional Meta-Analysis

    by Benedict Stanberry, Koen Deloose, Yann Gouëffic, Gilles Goyault, Giacomo Isernia, Ralph Jackson, Nils Kucher, Michael Lichtenberg, James McCaslin, Bruno Migliara, et al.

    Objective: Rotational percutaneous mechanical thrombectomy with adjunctive angioplasty, stenting or limited thrombolysis (rPMT+) has become commonplace in the treatment of acute and subacute limb ischaemia (SLI). This systematic review and proportional meta-analysis synthesises the available evidence on its safety and efficacy. Data Sources: MEDLINE, Embase and the Cochrane Library. Review Methods: We searched for studies (≥10 patients) published since January 1, 2012 (PROSPERO protocol CRD420251015846). Risk of bias was assessed using RoBANS 2. Proportional meta-analysis maximised representative sample sizes by incorporating both single-arm and comparative studies. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) evidence profiles were developed for each outcome of interest. Results: Twenty-four studies – 7 comparative and 17 single arm – containing 2954 procedures (2697 rPMT+, 257 controls) met eligibility criteria. There were no randomised controlled trials. The pooled technical success (TS) rate for rPMT+ was 98% (95% confidence interval [CI]: 97%–100%, p < .001). Amputation-free survival (AFS) was 96% (95% CI: 93%–98%, p < .001). Twelve-month primary patency (PP) was 68% (95% CI: 55%–79%, p < .001). The pooled rate of freedom from clinically-driven target lesion revascularisation was 85% (95% CI: 80%–90%, p < .001). No significant differences existed between acute, subacute and mixed subgroups. Procedure-related mortality was 0.5% (11 deaths in 2086 procedures from 17 studies) with most deaths occurring after adjunctive catheter-directed thrombolysis. Major adverse events occurred in 4% of procedures (95% CI: 1%–8%, p < .001) and distal embolisation in 8% (95% CI: 5%–11%, p < .001). rPMT+ reduced length of stay by 1.7 days versus alternatives (95% CI: 3.3%–0.1 days, p < .05). All outcomes demonstrated heterogeneity; GRADE assessment rated evidence certainty as low to very low. Conclusion: The evidence available from 24 real-world observational studies of 2954 procedures supports the use of rPMT+ in acute limb ischaemia and SLI – delivering an overall pooled TS rate of 98% and AFS rate of 96% with no significant differences between acute, subacute and mixed subgroups. rPMT+ is associated with shorter hospital stays than either surgery or thrombolysis. Clinical Impact: This systematic review and proportional meta-analysis synthesises 24 single-arm and comparative non-randomised studies encompassing nearly 3000 procedures to provide a comprehensive assessment of the safety and efficacy of rotational percutaneous mechanical thrombectomy in patients with acute and subacute lower limb ischaemia. It demonstrates that, when used for initial revascularisation prior to adjunctive angioplasty, stenting or limited thrombolysis, this endovascular approach delivers clinically valuable rates of technical success and amputation-free survival with notably high rates of freedom from clinically-driven target lesion revascularisation, acceptable primary patency, low procedural risk and significantly shorter hospital stays.

  • Negative pressure wound therapy made simple: expert panel recommendations

    by Mark Portou, Kris Bernaerts, Franco Bassetto, Mario Cherubino, Mark Collier, Christoph Hirche, Raymund E Horch, Julian W Mall, Gillian O' Brien, Alberto Piaggesi, et al.

    Objective: Wound management poses a substantial economic burden, and the prevalence of hard-to-heal (chronic) wounds is a growing health concern. Negative pressure wound therapy (NPWT), with and without instillation, is an adjunctive therapy commonly used to manage acute and hard-to-heal wounds and has demonstrated positive clinical outcomes. The variety of NPWT modalities, patient needs, wound characteristics and care requirements can make selecting the optimal system challenging, leading to uncertainty and inconsistent practices among new users, increasing the risk of suboptimal outcomes. This article provides practical guidance to help new NPWT users make confident, evidence-based decisions. Method: An expert panel was convened in Amsterdam, the Netherlands, in November 2023 to review published treatment guidelines and the current literature and to develop simplified recommendations on the use of NPWT in hospital and community care settings. Results: Expert panel members discussed published wound management evidence and their real-world experiences as wound management specialists to generate recommendations for healthcare professionals to aid them in the selection of NPWT modalities. Conclusion: This summary presents nine expert panel recommendations, including simplified risk assessment algorithms and guidance to improve NPWT use across clinical settings.

  • Open Access

    Consensus-Driven Vessel Preparation and Definitive Endovascular Treatment Strategies for Femoropopliteal Arterial Lesions Based on Plaque Morphology

    by Steven Kum, Sven Bräunlich, Ehrin J. Armstrong, Koen Deloose, Mark J. Portou, Marianne Brodmann, Edwaldo Edner Joviliano, Gabriel Fernando Mejia-Villate, Jinoo Kim, Chung-Ho Hsu, et al.


  • Open Access

    Rotational Percutaneous Mechanical Thrombectomy for Acute and Subacute Limb Ischaemia: a Systematic Review and Proportional Meta-analysis

    by Benedict Stanberry, Koen Deloose, Yann Gouëffic, Gilles Goyault, Giacomo Isernia, Ralph Jackson, Nils Kucher, Michael Lichtenberg, James McCaslin, Bruno Migliara, et al.

    Objective: Rotational percutaneous mechanical thrombectomy with adjunctive angioplasty, stenting or limited thrombolysis (rPMT+) has become commonplace in the treatment of acute and subacute limb ischaemia. This systematic review and proportional meta-analysis synthesises the available evidence on its safety and efficacy. Data Sources: MEDLINE, Embase and the Cochrane Library. ≥ Review Methods: We searched for studies (≥10 patients) published since 1 January 2012 (PROSPERO protocol CRD420251015846). Risk of bias was assessed using RoBANS 2. Proportional meta-analysis maximised representative sample sizes by incorporating both single-arm and comparative studies. GRADE evidence profiles were developed for each outcome of interest. Results: Twenty-four studies – seven comparative and 17 single arm – containing 2,954 procedures (2,697 rPMT+, 257 controls) met eligibility criteria. There were no randomised controlled trials. The pooled technical success (TS) rate for rPMT+ was 98% (95% CI: 97-100%, p p p p p p p <0.05). All outcomes demonstrated heterogeneity. GRADE assessment rated evidence certainty as low to very low. Conclusion: rPMT+ delivers consistently high TS and AFS rates, promising 12-month fCDTLR, acceptable PP, low procedural risk and shorter hospital stays than comparators. The consistency of favourable outcomes supports its use as a safe and effective treatment in appropriately selected ALI and SLI patients. WHAT THIS PAPER ADDS: This systematic review and proportional meta-analysis synthesises 24 single-arm and comparative non randomised studies encompassing nearly 3,000 procedures to provide a comprehensive assessment of the safety and efficacy of rotational percutaneous mechanical thrombectomy in patients with acute and subacute lower limb ischaemia. It demonstrates that, when used for initial revascularisation prior to adjunctive angioplasty, stenting or limited thrombolysis, this endovascular approach delivers consistently high rates of technical success and amputation-free survival with notably high rates of freedom from clinically-driven target lesion revascularisation, acceptable primary patency, low procedural risk and significantly shorter hospital stays.